Our Biosimilars pipeline focuses on autoimmune diseases and oncology. We also have candidates in early-phase development in these therapy areas.
Our Biosimilar products portfolio
The information on this page is intended for healthcare professionals based outside of the U.S. so that they may learn about our portfolio offering in their region.
Our Biosimilars portfolio focuses on autoimmune diseases and oncology. We also have candidates in early-phase development in these therapy areas.
At Fresenius Kabi, we are committed to providing valued biologic treatments through the development of immunology and oncology therapies in our expanding biosimilars portfolio.
Our portfolio includes biosimilars of adalimumab and tocilizumab (in development) in the autoimmune disease (immunology) therapy area, and a biosimilar of pegfilgrastim in the oncology therapy area.
In addition, we have candidates in early-phase development, in both autoimmune and oncology therapy areas.